rs10498830 - EYS
Magnitude 2.8 · 1 study on file
Reported associations
-
Whole genome sequence analysis of apparent treatment resistant hypertension status in participants from the Trans-Omics for Precision Medicine program - Unknown journal (n.d.) · Unknown authors · PubMed 38162683
ABSTRACT: Introduction: Apparent treatment-resistant hypertension (aTRH) is characterized by the use of four or more antihypertensive (AHT) classes to achieve blood pressure (BP) control. In the current study, we conducted single-variant and gene-based analyses of aTRH among individuals from 12 Trans-Omics for Precision Medicine cohorts with whole-genome sequencing data. Methods: Cases were defined as individuals treated for hypertension (HTN) taking three different AHT classes, with average systolic BP ≥ 140 or diastolic BP ≥ 90 mmHg, or four or more medications regardless of BP (n = 1,705). A normotensive control group was defined as individuals with BP < 140/90 mmHg (n = 22,079), not on AHT medication. A second control group comprised individuals who were treatment responsive on o
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
treatment-resistant hypertension specialist assessment Moderate
Genetic predisposition suggests earlier specialist evaluation may benefit carriers if hypertension develops and responds poorly to initial medications
If hypertension develops, discuss specialist referral timing with primary care provider
Screening
-
regular blood pressure monitoring Moderate
EYS rs10498830 C allele carriers have elevated risk of treatment-resistant hypertension in GWAS analysis
Check blood pressure at least annually starting in adulthood; discuss optimal screening schedule with provider